PET scan for neuroendocrine tumors
Part of Cancer clinical trials.
This trial tests a new PET scan tracer to find neuroendocrine tumors in the body. It may help doctors see where the tumors are and plan better treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with a neuroendocrine tumor.
- You have at least one suspicious spot seen on other scans or from your doctor's exam.
- You do not have another type of cancer.
- You do not have severe liver or kidney problems.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well a specific PET/CT scan using a radioactive tracer can detect or evaluate cancers. It may help doctors see where cancer is in the body more clearly.
This trial tests a new imaging method (68Ga-DOTA-mPNE PET/CT) to see if it can help detect cancers. It's for people who haven't had chemotherapy or radiation yet and will have a biopsy or surgery.
This trial looks at using a specific PET/CT scan (a whole-body imaging test) to help evaluate cancer that is confirmed or suspected. If you are eligible, you may receive this scan soon after a recent FDG PET/CT to compare or improve how cancers are identified.
This early-phase trial uses a special PET/CT scan to help evaluate neural crest tumors, which include conditions like neuroblastoma. It may help doctors understand how well the scan shows tumor activity to guide diagnosis and treatment planning.
This trial tests a special PET scan to better evaluate gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It may help your doctor see where the tumors are in your body.
This study uses a PET/CT scan with a small amount of radioactive tracer to see how neuroendocrine tumors are behaving in adults. It may help doctors better detect and evaluate these tumors, especially when symptoms suggest a carcinoid-type hormone problem.
Hear when a new Neuroendocrine Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.